Trial Profile
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- Acronyms Acthar Gel
- 10 Sep 2021 Status changed from recruiting to completed.
- 25 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jul 2021.
- 21 Jan 2020 Planned End Date changed from 1 Oct 2019 to 1 Jul 2021.